WELCOME TO OUR PARKINSON'S PLACE!

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

TRANSLATE

Monday, September 5, 2016

Hype about Parkinson’s drug is unwarranted

Sept. 5, 2016


WE WERE disappointed that the tone of the Stat article “The patients wait” further spread the unwarranted hype about nilotinib. For example, nilotinib is referred to as “the most promising new treatment for Parkinson’s disease in decades,” and in the online version, videos are shown of a patient before and after treatment with this drug. 
The published study involved only 12 patients, without a placebo group. The placebo effect is strong in Parkinson’s disease, and so no conclusions regarding symptomatic benefits can be made from the doctors’ and patients’ reports of clinical benefits. Parkinson’s disease patients have many reasons for hope, but exaggerating the significance of early clinical data is counterproductive. These words are not without consequences. Some doctors are now prescribing nilotinib to Parkinson’s disease patients despite a lack of sufficient data regarding efficacy or long-term safety in these patients.
On the other hand, nilotinib is indeed worthy of further study. The focus should be on how to move forward with the best-designed, scientifically rigorous placebo-controlled study as a step toward more definitively determining whether or not nilotinib will be of benefit for Parkinson’s disease patients.
Dr. David K. Simon
Associate professor of neurology
Harvard Medical School
Director
Parkinson’s Disease and Movement Disorders Center
Beth Israel Deaconess Medical Center
Dr. Michael A. Schwarzschild
Professor of neurology
Harvard Medical School
Director
Molecular Neurobiology Laboratory
Massachusetts General Hospital
Boston
The writers are members of the Linked Clinical Trials scientific committee established by the Cure Parkinson’s Trust, have received funding from the Michael J. Fox Foundation, and conduct clinical trials for Parkinson’s disease.
https://www.bostonglobe.com/opinion/letters/2016/09/04/hype-about-parkinson-drug-unwarranted/oCRWpsaqYzDaHIWI3Y0rQL/story.html

No comments:

Post a Comment